Phase 1b study of Foxy5 in Metastatic Breast, Colon or Prostate Cancer
Research type
Research Study
Full title
Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic response of Foxy-5 in Patients with Metastatic Breast-, Colon- or Prostate Cancer
IRAS ID
193654
Contact name
Ruth Plummer
Contact email
Sponsor organisation
Wnt Research AB
Eudract number
2015-004767-36
Duration of Study in the UK
1 years, 0 months, 29 days
Research summary
This project aims to study the safety, effectiveness and tolerability of a new medicine called ‘Foxy-5'. 'Foxy-5' is initially being tested in prostate, colon or breast cancer where the disease has spread to other parts of the body (called metastasis). It is intended for patients where other treatments for their cancer have failed and where there are no other treatment options available.
The study also aims to find the optimal dose Foxy-5 to give to patients by increasing the dose of Foxy-5 until the optimal dose is found.
Foxy-5 is similar to a naturally occurring protein in the body called Wnt-5a that is thought to stop the spread of cancer cells to different parts of the body. In an animal model, Foxy-5 has been shown to mimic the action of Wnt-5a and also stop the spread of cancer cells to other parts of the body.REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
16/NE/0031
Date of REC Opinion
24 Mar 2016
REC opinion
Further Information Favourable Opinion